Medraś Marek, Szczesny Magdalena
Pol Merkur Lekarski. 2003 Aug;15(86):111-4.
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancers. It is an infrequent, but serious clinical problem. This paper discusses epidemiology, potential risk factors, tumor histopathology, clinical features and treatment strategies of the disease. Hormonal, genetic and environmental factors associated with an increased risk of breast cancer in men have been reviewed. Authors suggest that there may be an association between long-term androgen therapy and breast cancer in men. This uncommon malignancy is most commonly seen in men over sixty years. Histologically MBC resembles that seen in women, although lobular cancer is rare in men. Tumors from men are more often estrogen-receptor positive. Treatment strategies draw from experience in women and usually begin with surgery. Modified radical mastectomy is the current treatment of choice for invasive cancer. Additional modalities include hormonal treatment, radio- and chemotherapy. Male breast cancer may be also a problem in the context of androgen replacement therapy during andropause.
男性乳腺癌(MBC)是一种罕见疾病,占所有乳腺癌的比例不到1%。它是一个不常见但严重的临床问题。本文讨论了该疾病的流行病学、潜在风险因素、肿瘤组织病理学、临床特征及治疗策略。对与男性患乳腺癌风险增加相关的激素、遗传和环境因素进行了综述。作者认为长期雄激素治疗与男性乳腺癌之间可能存在关联。这种不常见的恶性肿瘤最常见于60岁以上的男性。从组织学上看,男性乳腺癌与女性相似,不过小叶癌在男性中罕见。男性的肿瘤雌激素受体阳性更为常见。治疗策略借鉴了女性乳腺癌的治疗经验,通常始于手术。改良根治性乳房切除术是目前浸润性癌的首选治疗方法。其他治疗方式包括激素治疗、放疗和化疗。在男性更年期进行雄激素替代治疗时,男性乳腺癌也可能成为一个问题。